US Capitol Capsule: 'Innovative' Value-Based Pricing Strategies: Biopharma's Savior?
This article was originally published in Scrip
Executive Summary
With US insurers and pharmacy benefit managers (PBMs) increasingly becoming more and more aggressive about demanding better discounts and rebates from drug manufacturers and imposing more restrictions on what medicines the payers will include on their formularies, to survive, biopharmaceutical firms must bite the bullet and negotiate under value-based pricing schemes, said Dan Mendelson, CEO of the Washington-based analysis and consulting firm Avalere Health.